Interview with the CEO of Renatus, Heegon Kim

Heegon Kim, the CEO of Renatus is sharing their mission to revolutionize cholesterol modulation with safer and more effective cyclodextrin-based therapies.

Their lead candidate, RN-005, features cross-linked cyclodextrins, which are engineered to overcome the safety challenges of traditional cyclodextrins, such as the ototoxicity or “ear poisoning”, while maintaining high efficacy. Shifting their mechanism of action, Renatus' pipeline spans a range of cholesterol-driven diseases including Diabetic kidney diseases, Alzheimer’s, Niemann-Pick Type C or Atherosclerosis among others. Renatus is committed to improving the patient outcomes through its innovative approaches to cholesterol metabolism, making significant strides in tackling cholesterol-driven diseases.

Read the Bioneex Story with Renatus